表紙:SDN-037の新興薬剤に関する洞察と市場予測:2032年
市場調査レポート
商品コード
1381067

SDN-037の新興薬剤に関する洞察と市場予測:2032年

SDN-037 Emerging Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
SDN-037の新興薬剤に関する洞察と市場予測:2032年
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

SDN-037は、米国FDAが承認した白内障手術後の眼の痛みや炎症に対する新規の長時間作用型(1日2回)眼科用ステロイド製剤です。現在市販されているステロイド点眼薬は、4~6時間ごとに投与する必要があります。SPARCの製剤は、投与の利便性だけでなく、乳白色で投与後に視界がぼやける市販の製剤と比較して透明です。

今後数年間で、急性眼痛の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、SDN-037の優位性に影響を与える可能性のある機会を模索しています。急性眼痛に対する他の新興製品がSDN-037に厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要8ヶ国におけるSDN-037市場について調査し、市場の概要とともに、2024年~2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性眼痛に対するSDN-037の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • その他の開発活動
  • 製品概要

第3章 競合情勢(上市済み治療法)

第4章 競合情勢(後期段階の新興治療法)

第5章 SDN-037市場評価

  • 急性眼痛に対するSDN-037の市場展望
  • 主要8ヶ国市場分析
    • 主要8ヶ国市場における急性眼痛に対するSDN-037の市場規模
  • 国別市場分析
    • 米国
    • ドイツ
    • 英国
    • カナダ
    • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: SDN-037, Clinical Trial Description, 2023
  • Table 2: SDN-037, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: SDN-037 Market Size in the 8MM, in USD million (2019-2032)
  • Table 6: SDN-037 Market Size in the US, in USD million (2019-2032)
  • Table 7: SDN-037 Market Size in Germany, in USD million (2019-2032)
  • Table 8: SDN-037 Market Size in France, in USD million (2019-2032)
  • Table 9: SDN-037 Market Size in Italy, in USD million (2019-2032)
  • Table 10: SDN-037 Market Size in Spain, in USD million (2019-2032)
  • Table 11: SDN-037 Market Size in the UK, in USD million (2019-2032)
  • Table 12: SDN-037 Market Size in Canada, in USD million (2019-2032)
  • Table 13: SDN-037 Market Size in South Korea, in USD million (2019-2032)

List of Figures

  • Figure 1: SDN-037 Market Size in the 8MM, USD million (2019-2032)
  • Figure 2: SDN-037 Market Size in the United States, USD million (2019-2032)
  • Figure 3: SDN-037 Market Size in Germany, USD million (2019-2032)
  • Figure 4: SDN-037 Market Size in France, USD million (2019-2032)
  • Figure 5: SDN-037 Market Size in Italy, USD million (2019-2032)
  • Figure 6: SDN-037 Market Size in Spain, USD million (2019-2032)
  • Figure 7: SDN-037 Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: SDN-037 Market Size in Canada, USD million (2019-2032)
  • Figure 9: SDN-037 Market Size in South Korea, USD million (2019-2032)
目次
Product Code: DIDM1082

“"SDN-037 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SDN-037 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SDN-037 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SDN-037 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SDN-037 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SDN-037 is a novel long-acting (twice-a-day) formulation of a US FDA-approved ophthalmic steroid for eye pain and inflammation after cataract surgery. Currently marketed steroidal eye drops requires administration every 4-6 h. Apart from providing dosing convenience, SPARC's formulation is clear compared to a marketed formulation which is milky, resulting in blurring of vision after administration.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the SDN-037 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
  • Elaborated details on SDN-037 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the SDN-037 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
  • The report also covers the patents information with expiry timeline around SDN-037.
  • The report contains forecasted sales of SDN-037 for acute ocular pain till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
  • The report also features the SWOT analysis with analyst views for SDN-037 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SDN-037 Analytical Perspective by DelveInsight

In-depth SDN-037 Market Assessment

This report provides a detailed market assessment of SDN-037 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

SDN-037 Clinical Assessment

The report provides the clinical trials information of SDN-037 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SDN-037 dominance.
  • Other emerging products for acute ocular pain are expected to give tough market competition to SDN-037 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SDN-037 in acute ocular pain.
  • Our in-depth analysis of the forecasted sales data of SDN-037 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SDN-037 in acute ocular pain.

Key Questions:

  • What is the product type, route of administration and mechanism of action of SDN-037?
  • What is the clinical trial status of the study related to SDN-037 in acute ocular pain and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SDN-037 development?
  • What are the key designations that have been granted to SDN-037 for acute ocular pain?
  • What is the forecasted market scenario of SDN-037 for acute ocular pain?
  • What are the forecasted sales of SDN-037 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
  • What are the other emerging products available and how are these giving competition to SDN-037 for acute ocular pain?
  • Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. SDN-037 Overview in Acute ocular pain

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SDN-037 Market Assessment

  • 5.1. Market Outlook of SDN-037 in Acute ocular pain
  • 5.2. 8MM Analysis
    • 5.2.1. Market Size of SDN-037 in the 8MM for Acute ocular pain
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of SDN-037 in the United States for Acute ocular pain
    • 5.3.2. Market Size of SDN-037 in Germany for Acute ocular pain
    • 5.3.3. Market Size of SDN-037 in France for Acute ocular pain
    • 5.3.4. Market Size of SDN-037 in Italy for Acute ocular pain
    • 5.3.5. Market Size of SDN-037 in Spain for Acute ocular pain
    • 5.3.6. Market Size of SDN-037 in the United Kingdom for Acute ocular pain
    • 5.3.7. Market Size of SDN-037 in Canada for Acute ocular pain
    • 5.3.8. Market Size of SDN-037 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options